MAIA Biotechnology (MAIA) Accounts Payables (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Accounts Payables for 6 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables rose 64.73% year-over-year to $2.8 million in Q2 2026; TTM through Jun 2026 was $2.8 million, a 64.73% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 34.8% from the prior year.
• Accounts Payables was $2.8 million for Q2 2026 at MAIA Biotechnology, down from $3.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $3.2 million in Q3 2025 and troughed at $1.0 million in Q3 2022.
• A 5-year average of $1.7 million and a median of $1.5 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables declined 18.42% in 2024 and surged 175.65% in 2025, its largest moves.
• Over 5 years, Accounts Payables stood at $1.2 million in 2022, then soared by 40.59% to $1.6 million in 2023, then slipped by 7.7% to $1.5 million in 2024, then jumped by 34.8% to $2.0 million in 2025, then soared by 39.23% to $2.8 million in 2026.
• The last three Accounts Payables figures came in at $2.8 million (Q2 2026), $3.0 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.